Edifice Health announces investment from Human Longevity, Inc. to transform how we measure inflammatory and immune health to help change the course of our aging process.

Edifice Health announces investment from Human Longevity, Inc. to transform how we measure inflammatory and immune health to help change the course of our aging process.

San Mateo, CA, September 22, 2020 – Edifice Health, a spin-off company from a NIH funded 10-year scientific research study by Stanford University has developed the first biomarker composite scoring system to measure inflammatory and immune health. With the recent investment from Human Longevity, Inc.’s (HLI) corporate venture arm called Human Longevity and Performance Impact Venture Fund, the company launches with Series A financing and a model that tackles chronic inflammation, the root cause of most age-related diseases.

Leveraging artificial intelligence modeling, Edifice Health’s Inflammatory Age® technology is the first metric for early detection of systemic chronic inflammation and provides previously unattainable insights into taking action on healthy versus unhealthy aging. To provide consumers with a comprehensive view into their immune health, Edifice Health is collaborating with industry players in food and nutraceuticals to derive data-driven personalized nutrition solutions to improve the Inflammatory Age® results of an individual.

Wolfgang Daum, PhD, Edifice Health CEO, said “We are excited to partner with HLI on the common ground of providing insights into the state of our inflammatory and immune health to prevent disease.” Daum added, “Coupled with the recent market shift focusing on preventative care, consumers are increasingly interested in tracking their immune health in more tangible ways and are constantly finding ways to determine their biological health status.”

HLI is an innovator and leader in the delivery of data-driven, predictive precision health intelligence. David S. Karow, MD, PhD, President, HLI, stated “We believe Edifice’s Inflammatory Age® platform can allow our customers and our network of longevity physicians to measure immune health in order to increase factors for healthier living. Our goal is to increase the healthy, high-performance life span for our clients and insights into their immune health will play an important part in achieving this goal.”

About Edifice Health, Inc.
Edifice Health is a spin-off company from Stanford University focused on the identification of immune system biomarkers of age-related diseases to delay and prevent major chronic diseases. The Inflammatory Age® technology is a novel metric for the early detection of systemic chronic inflammation and the degree of a weakened immunity. The Inflammatory Age® can be improved with personalized health interventions identified by Edifice Health.
www.edificehealth.com

About Human Longevity, Inc.
Human Longevity is a genomics-based, health intelligence company empowering proactive healthcare and enabling a life better lived. HLI’s business focus includes the Health Nucleus, a genomic-powered, precision medicine center which uses whole-genome sequencing analysis, advanced imaging, and blood analytics, to deliver the most complete picture of individual health.
www.healthnucleus100plus.com

Human Longevity and Performance Impact Venture Fund.
HLPIVF is an early stage venture capital fund dedicated to providing resources, insight, and leadership to companies whose mission is to improve human health and drive longevity through technology, predictive analytics and patient care.

2020-09-22T14:07:45-07:00September 22nd, 2020|News|
Go to Top